Woodline Partners’s Cabaletta Bio CABA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$10M Buy
5,200,642
+1,000,500
+24% +$2.82M 0.03% 557
2026
Q2
$13.1M Buy
4,200,142
+2,949,900
+236% +$9.7M 0.04% 472
2026
Q1
$3.36M Hold
1,250,242
– – 0.01% 729
2025
Q4
$2.74M Sell
1,250,242
-885,106
-41% -$2.19M 0.01% 734
2025
Q3
$5M Buy
2,135,348
+916,884
+75% +$1.57M 0.02% 568
2025
Q2
$1.85M Buy
+1,218,464
New +$1.9M 0.01% 733
2024
Q3
– Sell
-242,981
Closed -$1.82M – 612
2024
Q2
$1.82M Buy
242,981
+318
+0.1% +$3.9K 0.02% 426
2024
Q1
$4.14M Buy
242,663
+1,210
+0.5% +$26K 0.04% 379
2023
Q4
$5.48M Buy
241,453
+107,269
+80% +$1.8M 0.06% 307
2023
Q3
$2.04M Buy
+134,184
New +$1.83M 0.02% 399

Other funds holding CABA

Woodline Partners's CABA Position: Q3 2026 in Review

Woodline Partners increased its Cabaletta Bio (CABA) stake by 24% in Q3 2026, buying an estimated $2.82M and bringing the position to 5,200,642 shares worth $10M. The position accounts for 0.03% of the portfolio, ranked #557.

Woodline Partners first reported a position in CABA in Q3 2023 and has held it in 10 quarters since. The position peaked at $13.1M in Q2 2026. 163 funds tracked by Wall St. Rank hold CABA as of Q3 2026.

  • Woodline Partners held 5,200,642 shares of Cabaletta Bio worth $10M as of Q3 2026.
  • Woodline Partners bought 1,000,500 Cabaletta Bio shares in Q3 2026, an estimated $2.82M.
  • Cabaletta Bio made up 0.03% of Woodline Partners's portfolio in Q3 2026, its #557 holding.
  • Woodline Partners first reported a position in Cabaletta Bio in Q3 2023 and has held it in 10 quarters since.
  • Woodline Partners's Cabaletta Bio position peaked at $13.1M in Q2 2026.
  • 163 funds tracked by Wall St. Rank held Cabaletta Bio as of Q3 2026.

Based on Woodline Partners's 13F filing for Q3 2026, filed 16 Nov 2026.